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Abstract
Background: Invasive candidiasis is an important nosocomial infection associated with high mortality among
immunosuppressive or critically ill patients. We described the incidence of invasive candidiasis in our hospital over
6 years and showed the antifungal susceptibility and genotypes of the isolated yeast.
Method: The yeast species were isolated on CHROMagar Candida medium and identified using an yeast
identification card, followed by analysis of the D1/D2 domain of 26S rDNA. The susceptibilities of the isolates to
flucytosine, amphotericin B, fluconazole, itraconazole, and voriconazole were tested using the ATB FUNGUS 3
system, and that to caspofungin was tested using E-test strips. C. albicans was genotyped using single-strand
conformation polymorphism of CAI (Candida albicans I) microsatellite DNA combined with GeneScan data.
Results: From January 2006 to December 2011, a total of 259 isolates of invasive Candida spp. were obtained from
253 patients, among them 6 patients had multiple positive samples. Ninety-one stains were from blood and 168
from sterile fluids, accounting for 6.07% of all pathogens isolated in our hospital. Most of these strains were
C. albicans (41.29% in blood/59.06% in sterile body fluids), followed by C. tropicalis (18.06%/25.72%), C. parapsilosis
(17.42%/5.43%), C. glabrata (11.61%/3.99%) and other Candida spp. (11.61%/5.80%). Most Candida spp. were isolated
from the ICU. The new species-specific CLSI candida MIC breakpoints were applied to these date. Resistance to
fluconazole occurred in 6.6% of C. albicans isolates, 10.6% of C. tropicalis isolates and 15.0% of C. glabrata isolates.
For the 136 C. albicans isolates, 54 CAI patterns were recognized. The C. albicans strains from blood or sterile body
fluids showed no predominant CAI genotypes. C. albicans isolates from different samples from the same patient
had the same genotype.
Conclusions: Invasive candidiasis has been commonly encountered in our hospital in the past 6 years, with
increasing frequency of non-C. albicans. Resistance to fluconazole was highly predictive of resistance to
voriconazole. CAI SSCP genotyping showed that all C. albicans strains were polymorphic. Invasive candidiasis were
commonly endogenous infection.
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Background
In the early 1980s, fungi have emerged as major causes
of human disease, especially in immunocompromised
and hospitalized patients [1]. Candida spp. are the
fourth most common pathogens in nosocomial blood-
stream infections (BSIs), and they account for 12% of all
hospital-acquired BSIs in the United States [2]. The
mortality of candidemia in adults and neonatal children
was estimated to be 15%–25% and 10%–15% in the
United States, respectively [3]. Further, studies have
shown that Candida infection can extend the duration
of hospital stay [4], increase the cost of medical care [5],
and lead to a high mortality (30%–40%) [6]. In recent
years, non-C. albicans spp. have been detected more
commonly in candidemia [7,8]. Both C. albicans and
non-C. albicans cause invasive candidiasis, and the anti-
fungal resistance of invasive Candida aggravates the
situation. Some reports on Candida resistance to anti-
fungals showed that resistance could make therapy more
difficult [9,10]. The species and antifungal resistance of
Candida differ among geographies, and it is necessary to
survey the prevalence and drug resistance of Candida
spp. in different locations in order to ensure effective an-
tifungal therapy against invasive Candida.
Few studies on the long-term monitoring of the inci-
dence and antifungal susceptibilities of invasive Candida
spp. have been reported from China. This study aims to
describe the trend of invasive candidiasis in a teaching
hospital during the last 6 years.
Methods
Study population and data collection
The study was conducted in Beijing Chaoyang Hospital,
a teaching facility of the Capital Medical University in
Beijing, China. According to the diagnostic criteria, all
patients with invasive candidiasis were enrolled from dif-
ferent wards from 2006 to 2011. The following informa-
tion was collected including age, sex, underlying diseases,
et al. This investigation had the approval of the Ethics
Committee of Beijing Chaoyang Hospital and informed
consent was obtained from all study subjects or their next
of kin.
Candida strain collection
A total of 259 isolates of invasive Candida spp. were
obtained from 253 patients, among them 6 patients had
multiple positive samples. Invasive Candida strains were
isolated from blood (91) and sterile samples (168) (includ-
ing ascitic fluid, bile,central venous catheter, pleural fluid);
the total of 259 samples accounted for 6.07% of all patho-
gens (5.75% of 1583 from blood and 6.27% of 2684 patho-
gens from sterile fluids) isolated in Beijing Chao-yang
Hospital during the study period. Patients come from 13
provinces in china, mainly in northern china (including
Beijing, Shanxi, Inner Mongolia, Heilongjiang et al.) Most
of the Candida spp. were isolated from patients in the in-
tensive care unit (ICUs). The Candida strains were primar-
ily cultured on CHROMAgar Candida medium (JinZhang,
Tianjing China) and identified using an yeast identifica-
tion card (BioMérieux, France) or the API 20C AUX
system (BioMérieux, France), followed by sequence
analysis of the D1/D2 domain in the 26S rDNA [11].
Quality control isolates included C. albicans ATCC90028,
C. parapsilosis ATCC22019, and C. krusei ATCC6258.
Antifungal drug susceptibility test
A total of 240 Candida strains were tested for antifungal
susceptibility. The susceptibility of these strains to 6 anti-
fungal drugs was tested in vitro. Flucytosine, amphotericin
B, fluconazole, voriconazole, and itraconazole were
tested using the ATB FUNGUS 3 system (1000723260;
BioMérieux, France), and caspofungin, using the E-test
(BJ3625 AB Biodisk; Solna, Sweden). For fluconazole,
voriconazole, and itraconazole, the minimal inhibitory
concentration (MIC) was determined by determining the
concentration at which a prominent reduction in the yeast
cell count was observed after 24 h of treatment. For the
caspofungin, the MIC was determined by detection of
a significant reduction in growth after 24 h of incuba-
tion. The MIC for amphotericin B and flucytosine
were defined as the lowest concentration at which no
visible growth was detected. Recently approved CLSI 24 h
resistance breakpoints for fluconazole,voriconazole and
echinocandins were used [12]: isolates of C. albicans,
C. tropicalis and C. parapsilosis with an MIC ≥ 8 μg/ml
and isolates of C. glabrata with an MIC ≥ 64 μg/ml were
considered resistant to fluconazole; isolates of C. albicans,
C. tropicalis and C. parapsilosis with an MIC ≥ 1 μg/ml
were considered resistant to voriconazole; isolates of
C. albicans and C. tropicalis with an MIC ≥ 1 μg/ml
were considered resistant to caspofungin, isolates of
C. parapsilosis with an MIC ≥ 8 μg/ml were consid-
ered resistant to caspofungin, isolates of C. glabrata
with an MIC ≥ 0.5 μg/ml were considered resistant to
caspofungin. Data were reported as the MIC ranges;
the MIC50 and MIC90 values; and the number of re-
sistant (R) isolates.
DNA extraction and PCR
DNA extraction and PCR amplification of CAI microsat-
ellite DNA were performed according to the methods of
[13]. The microsatellite locus CAI was amplified by PCR
(forward primer, 5′-ATG CCA TTG AGT GGA ATT
GG-3′; reverse, 5′-AGT GGC TTG TGT TGG GTT
TT-3′). For GeneScan analysis, the forward primer was
fluorescently labeled with 6-carboxyfluorescein at the 5′
end. PCR amplification was performed in a thermocycler
(ICycler; Bio-Rad, Hercules, CA) with the following
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program: initial denaturing step at 95°C for 4 min; 33 cy-
cles of denaturation at 95°C for 30 s, annealing at 60°C
for 30 s, and extension at 72°C for 1 min; and a final ex-
tension step at 72°C for 7 min.
Genotype analysis
Genotype analysis of the amplified CAI fragments was
carried out using the methods described by [14]. The
sizes of the PCR products were automatically deter-
mined using the ABI 370 genetic analyzer (Applied
Biosystem, Foster City, CA). Because of the diploid
nature of C. albicans, the CAI genotypes of the
strains were designated by the number of trinucleo-
tide repeat units in both alleles of the microsatellite
locus [14].
Statistical analysis
Drug susceptibility testing was analyzed using WHONET
5.6. Data were analyzed with SPSS 17.0 (SPSS Inc.,
Chicago, IL). Categorical variables were compared using




According to the diagnostic criteria of invasive can-
didiasis [15], a total of 253 patients were enrolled:
male (170/253) 67.19%, female (83/253) 32.81%. The
mean age was 65.08 ± 13.87 ys. The incidence rate of
invasive candidiasis was 0.25 cases per 1,000 admis-
sions from 2006–2011. The mortality rate at 6 weeks
in ICUs (39.73%) was higher than that in other wards
(17.39%), P < 0.05. The types of infection were blood-
stream infection (approximately 35%), abdominal in-
fection (approximately 35%), biliary tract infection
(approximately 18%), catheter related blood stream in-
fection (approximately 7%), and chest infection (ap-
proximately 6%), respectively.
Distribution of Candida
A total of 91 Candida strains were isolated from
blood, which account for 5.75% of the 1583 pathogens
isolated from blood from January 2006 to December
2011. The annual rates of candidemia over the 6 years
of the study were as follows: 8.8%, 7.9%, 4.8%, 5.9%,
4.7%, and 2.4%. Further, 168 Candida strains were
collected from sterile fluids (ascitic fluid, bile, central
venous catheter and pleural fluid), which accounted
for 6.27% of the 2684 pathogens isolated from sterile
fluids (Figure 1). The distribution of these 259 inva-
sive candidiasis specimens was as follows: blood
35.14%, ascitic fluid 35.03%, bile 17.53%, central ven-
ous catheter fluid 6.50%, and pleural fluids 5.80%
(Figure 2). Most of these strains were C. albicans (41.29%
in blood/59.06% in sterile body fluids), followed by C.
tropicalis (18.06%/25.72%), C. parapsilosis (17.42%/5.43%),
C. glabrata (11.61%/3.99%) and other Candida spp.
(11.61%/5.80%) (Figure 3).
The top 3 wards in which candidemia occurred were
the ICUs (43.23%) and the hematology (16.13%) and the
urology (10.32%). The wards in which Candida spp.
were most frequently isolated from sterile fluids were
the ICUs (41.91%) and the interventional radiology
(18.15%) and the hepatobiliary (10.56%). Thus, our data
showed that most patients with nosocomial candidasis
were from the ICUs.
Susceptibility of antifungal drugs
The susceptibilities of the 240 yeast strains to the 6 anti-
fungal drugs are shown in Table 1. Most Candida strains
were sensitive to all the antifungal drugs, although C.
glabrata and C. tropicalis showed decreased sensitivity
to triazole drugs (less than 90%). The percentages of
isolates in the R categories were 7.5% for fluconazole
and 5.4% for voriconazole, respectively. Caspofungin
and amphotericin B exhibited excellent antifungal ac-
tivity against all Candida species. The MIC of flucon-
azole was ≥8 μg/ml for C. albicans isolates (6.6%) and
that of voriconazole was ≥1 μg/ml (2.9%). Further, the
MIC of fluconazole was ≥8 μg/ml for C. tropicalis
isolates (10.6%) and that of voriconazole was ≥1 μg/ml
(10.6%). The MIC of fluconazole was ≥64 μg/ml for C.
glabrata isolates (15.0%). Three of 136 C. albicans
isolates (approximately 2%) were resistant to both
FLC (MIC ≥ 8 μg/ml) and VRC (MIC ≥ 1 μg/ml). Six
of 59 C. tropicalis isolates (approximately 10%) had
FLC MIC ≥ 8 μg/ml and VRC ≥ 1 μg/ml. Three of 20
C. glabrata isolates (approximately 15%) had FLC
MIC ≥ 64 μg/ml and VRC ≥ 8 μg/ml. No isolate was
resistant to all existing classes. Cross-resistance to tri-
azole antifungal drugs was found in 2.9% C. albicans
and 10.6% C. tropicalis isolates. Resistance to flucona-
zole was highly predictive of voriconazole resistance.
No statistically significant differences in azole resist-
ance (P > 0.05) were observed for C. albicans, C.
tropicalis, and C. glabrata isolated from either blood
or sterile fluids.
CAI genotypes of C. albicans
Genotype analysis was conducted for all 136 C. albicans,
54 CAI patterns were recognized. The overall frequen-
cies of the dominant genotypes were as follows: 18–26,
7.40%; 16–21, 6.48%; 21–21, 5.55%; 11–11, 5.55%; 26–26,
4.63%; 25–33, 4.63%; 11–20, 4.46%; 11–18, 3.70%; and
18–18, 3.70%. In 9 cases, the genotypes of C. albicans
isolates from different samples (blood, catheter fluid,
ascitic fluid, and bile) from the same patient were
identical.
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Discussion
This study described the distribution, in vitro antifun-
gal susceptibilities, and genotyping results of invasive
Candida spp. isolated between 2006 and 2011 from
Beijing Chaoyang hospital in China.
The results showed that invasive candidiasis has fre-
quently occurred in our hospital in the past 6 years. The
average isolation rate of Candida spp. was 6.07% among
all pathogens isolated from blood and sterile fluid sam-
ples. In most cases, the invasive candidiasis occurred in
the ICUs, indicating that more attention must be paid to
ICU patients in order to prevent them from contracting
this disease. Although C. albicans was the most predom-
inant species, the frequency at which non-albicans Can-
dida were detected increased obviously over the study
period. In our hospital, in more than half the recent cases
of candidemia, the causative organisms were non-albicans
Candida strains, C. tropicalis, C. parapsilosis, and C.
glabrata were the most common among the non-albicans
Candida spp. detected, in accordance with reports by
Pereira GH, et al. [16,17]. In the case of the blood samples,
C. albicans no longer comprised the majority of isolated
but remained the most frequently isolated species
(41.29%), followed by C. tropicalis (18.06%), C. parapsilosis
Figure 2 Distribution of Candida spp. in different samples (n = 259). The distribution of the 259 invasive candidiasis specimens was as
followed: blood 35.14%, ascitic fluid 35.03%, bile 17.53%, central venous catheter fluid 6.50%, and pleural fluids 5.80%.
Figure 1 Changes in the isolation rate of Candida spp. in the last 6 years. The annual rates of invasive candidiasis from 2006 to 2011 were
showed in the figure, according to the identification of Candida strains from bloodstream and sterile fluids (ascitic fluid, bile, central venous
catheter and pleural fluid).
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Table 1 In vitro antifungal susceptibility testing of 240 clinical isolates to 6 antifungal agents
Species
(No of isolates)




All isolates (240) Fluconazole 1– > 128 1 4 7.5
Voriconazole(except C. glabrata) 0.06– > 8 0.064 0.25 5.4
Itraconazole(limit C.albicans only) 0.125– > 4 0.125 0.5 4.9
Caspofunginb 0.032–2 0.125 0.5 0
Flucytosine < 4–16 4 4
Amphotericin B < 0.5–0.5 0.5 0.5
C. albicans (136) Fluconazole 1– > 128 1 2 6.6
Voriconazole 0.06– > 8 0.064 0.064 2.9
Itraconazole 0.125– > 4 0.125 0.125 4.9
Caspofunginb 0.032–0.38 0.094 0.19 0
Flucytosine < 4–16 4 4
Amphotericin B < 0.5–0.5 0.5 0.5
C.tropicalis (59) Fluconazole 1– > 128 1 128 10.6
Voriconazole 0.06– > 8 0.064 8 10.6
Itraconazole 0.125– > 4 0.125 4
Caspofunginb 0.032–0.38 0.094 0.19 0
Flucytosine < 4–4 4 4
Amphotericin B < 0.5–0.5 0.5 0.5
C. paraps-ilosis (25) Fluconazole < 1–2 1 1 0
Voriconazole < 0.06–0.25 0.064 0.064 0
Itraconazole < 0.125–0.25 0.125 0.125
Caspofunginb 0.38–2 1 1.5 0
Flucytosine < 4– > 16 4 16
Amphotericin B < 0.5–0.5 0.5 0.5
C.glabrata (20) Fluconazole 1–64 2 64 15.0
Voriconazole 0.06–8 0.125 8
Itraconazole 0.125– > 4 0.5 4
Caspofunginb 0.047–0.38 0.19 0.25 0
Flucytosine < 4–4 4 4
Amphotericin B < 0.5–0.5 0.5 0.5
Footnote: aMIC50, 50% minimal inhibitory concentration; MIC90: 90% minimal inhibitory concentration.
bCaspofungin tested using E-test strips.
Figure 3 Distribution of Candida spp. in blood and sterile fluids samples. Most of these strains were C. albicans (41.29% in blood/59.06% in
sterile fluids), followed by C. tropicalis (18.06%/25.72%), C. parapsilosis (17.42%/5.43%), C. glabrata (11.61%/3.99%) and other Candida
spp. (11.61%/5.80%).
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(17.42%), and C. glabrata (11.61%). In the case of the ster-
ile samples, C. albicans was the most commonly isolated
organism (59.06%), followed by C. tropicalis (25.72%), C.
parapsilosis (5.43%), and C. glabrata (3.99%). It is reported
that C. glabrata is No.4 among the most isolated species,
which are similar to our findings, but different from those
reported from Europe and the US [1,18,19].
C. abicans has traditionally been the leading cause of
candidemia worldwide, with the proportion of C.abicans
infections decreasing and proportion of non-C.abicans in-
fections increasing, especially C. tropicalis, C. parapsilosis
and C. glabrata. The trend has also been observed in this
study, the proportion of C. abicans candidemia cases de-
creased from 54% to 41%. At the same time, the propor-
tion of C. parapsilosis candidemia, C. glabrata candidemia
and C. tropicalis candidemia cases rose from 12% to 17%,
7% to 12% and 15% to 18%, respectively. In the ARTEMIS
DISK global antifungal surveillance project undertaken
between 1997 and 2007, 90% of infections were found
to be caused by 4 Candida species, i.e., C. albicans,
C. glabrata, C. parapsilosis, and C. tropicalis [20].
This distribution is similar to our study, C. abicans,
C.tropicalis,C. parapsilosis and C. glabrata still com-
prise 92.67% of all isolates, that has not substantially
changed in 20 years in the US [21]. During the last
decade, the frequency of detection of the latter 3 spe-
cies has been increasing in many countries, including
China [22-24]. The widespread use of fluconazole
may change the epidemiology of infections by non-
albicans Candida, especially azole-resistant Candida
spp. [25,26]. The shift to non-albicans Candida spe-
cies is also significant because of the newest class of
antifungal agents, so the caspofungin, are not cur-
rently recommended as primary therapy against C.
parapsilosis, the third most common species.
Few studies have conducted long-term research on in-
vasive Candida in China. The antifungal resistance rate
in our study was higher than that reported by Guiyang
in 2009 [27] and Hong Kong in 2011 [28]. However,
none of the isolates in this study were resistant to
caspofungin and amphotericin B. More than 90% of the
C. albicans isolates were susceptible to all antifungal
drugs between 2006 and 2011. We found that flucona-
zole resistance in C. albicans increased from 2.2% to
6.6% and in C.tropicalis, increased from 5.1% to 10.6%.
There was also,a trend toward increased resistance to
azoles in an Italian study [29]. We also found cross-
resistance in our study, in agreement with previous re-
ports from other countries [9,30]. A surveillance from
41 institutions participated study had shown that resist-
ance to fluconazole was highly predictive of resistance to
voriconazole [22]. In our study, all of the C. tropicalis
isolates resistant to FLC (MIC ≥ 8 μg/ml) were also
resistant to VRC (MIC ≥ 1 μg/ml). The same result in C.
glabrata isolates which had FLC MIC ≥ 64 μg/ml and
VRC ≥ 8 μg/ml was also observed. Therefore, we inferred
that resistance to fluconazole highly tend to predictive of
voriconazole resistance for C. glabrata and C. tropicalis.
Fifty-four CAI patterns were recognized from the 136
C. albicans isolates. CAI SSCP genotyping showed that
the C. albicans strains were polymorphic. C. albicans
isolates in different samples from the same patient had
the same genotype. Compared to Li’s study [13], we
found more patterns. These results implied that the
genotypic distribution of C. albicans strains may be vari-
ous in different samples. Isolates in different samples
from the same patient showed exactly the same CAI
SSCP pattern (e.g. isolates from patients CY61, CY65,
CY66, CY69, CY141, CY119, CY123, CY68 and CY154
in Table 2), indicating that the infection was mainly en-
dogenous [14,31].
Conclusions
In summary, this study showed the epidemiology and
antifungal resistance of invasive Candida spp. isolated
from Beijing Chaoyang hospital between 2006 and
2011. C. albicans was the most frequently isolated
species, compared to the non-albicans Candida spp.
Table 2 Different specimens, isolation times, and
genotypes of clinical samples
No. patient Isolation time Specimen CAI* genotype
CY61A 2010-08-20 blood 25-35
CY61B 2010-08-20 ascitic fluid 25-35
CY65A 2010-02-25 blood 11-20
CY65B 2010-02-25 catheter fluid 11-20
CY66A 2010-03-30 blood 21-21
CY66B 2010-03-29 catheter fluid 21-21
CY69A 2010-08-20 blood 16-21
CY69B 2010-08-23 catheter fluid 16-21
CY141A 2011-01-02 blood 32-46
CY141B 2011-01-07 catheter fluid 32-46
CY119A 2010-01-10 blood 16-18
CY119B 2010-01-07 ascitic fluid 16-18
CY123A 2010-04-14 ascitic fluid 17-28
CY123B 2010-04-14 catheter fluid 17-28
CY68A 2010-03-23 blood 25-33
CY68B 2010-03-20 catheter fluid 25-33
CY68C 2010-03-22 ascitic fluid 25-33
CY154A 2011-09-26 blood 16-21
CY154B 2011-09-26 catheter fluid 16-21
CY154C 2011-10-01 bile 16-21
CY154D 2011-10-04 ascitic fluid 16-21
*CAI CA is the abbreviation of Candida albicans, followed by the roman
numeral I.
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Although the overall rates of resistance to antifungal
agents remain low, species-specific raise some concerns,
especially C. tropicalis and C. glabrata were the most fre-
quent detected among organisms resistant to fluconazole.
Currently, Caspofungin and amphotericin B are highly ef-
fective in vitro against all Candida species. Most of the in-
vasive candidiasis cases occurred in the ICU, so careful
attention should be paid to ICU patients to prevent them
from contracting this disease. Genotyping of CAI SSCP
showed that the C. albicans strains were polymorphic
from blood and sterile samples and isolates from different
samples of the same patient had the same genotype.
Abbreviations
CAI SSCP: Single-strand conformation polymorphism; ICU: Intensive care unit;
MIC: Minimal inhibitory concentration; R: Resistant.
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